Millennium Management
AGMB

Millennium Management’s AgomAb Therapeutics NV AGMB Stock Holding History

Millennium Management’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-95,233
Closed -$999K – 6608
2026
Q1 		$999K Buy
+95,233
New +$1.35M ﹤0.01% 4392

Other funds holding AGMB

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management's AGMB Position: Q2 2026 in Review

Millennium Management sold out of AgomAb Therapeutics NV (AGMB) in Q2 2026, closing a stake of 95,233 shares — an estimated $999K sold.

Millennium Management first reported a position in AGMB in Q1 2026 and held it in 1 quarter. The position peaked at $999K in Q1 2026. 34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

  • Millennium Management reported no remaining AgomAb Therapeutics NV position as of Q2 2026 after selling out during the quarter.
  • Millennium Management sold 95,233 AgomAb Therapeutics NV shares in Q2 2026, an estimated $999K.
  • Millennium Management first reported a position in AgomAb Therapeutics NV in Q1 2026 and held it in 1 quarter.
  • Millennium Management's AgomAb Therapeutics NV position peaked at $999K in Q1 2026.
  • 34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.